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ABSTRACT 
 
Chronic inflammation in asthma is a key feature of the disease and monitoring is an 
essential component of asthma management. Inflammation is present in both central and 
peripheral bronchi and can be measured by non invasive markers, such as fractional 
exhaled nitric oxide (FeNO). FeNO is increased in asthmatics, as compared to normal 
subjects and is lowered by inhaled corticosteroids (ICS) with a dose-response 
relationship that is more evident for asthmatic patients with high levels of FeNO. FeNO 
measuring is easy to be performed in almost all patients including children and can be 
helpful as a tool contributing to asthma diagnosis and evaluation of the response to 
antinflammatory therapy with ICS. Smoking affects FeNO measurements and this has 
to be considered when evaluating patients with asthma who smoke. The different 
measurement of bronchial and alveolar FeNO can give information on the distribution 
of inflammation in the bronchial tree and is of particular interest for clinical 
pharmacology. Nonetheless, the clinical application of FeNO still needs to be clarified 
but it is clearly nowadays one of the most used non-invasive markers giving information 
on the inflammatory component of the disease.  
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EXHALED NITRIC OXIDE AND AIRWAY INFLAMMATION 
 
Asthma is a respiratory disease associated with airway hyperresponsiveness that 
leads to recurrent episodes of wheezing, breathlessness, chest tightness, and coughing, 
particularly at night or in the early morning. These episodes are usually associated with 
widespread, but variable, airflow obstruction within the lung that is often reversible 
either spontaneously or with treatment. Airway narrowing is the final common pathway 
leading to symptoms and physiological changes in asthma. Several factors contribute to 
the development of airway narrowing in asthma but the most important is chronic 
inflammation of the lower airways in which many cells and cellular elements play a role.  
There is now good evidence (1) that the clinical manifestations of asthma-
symptoms, sleep disturbances, limitations of daily activity, impairment of lung function, 
and use of rescue medications-can be controlled with appropriate treatment, mainly 
antinflammatory drugs, such as inhaled corticosteroids (ICS). When asthma is 
controlled, there should be no more than occasional recurrence of symptoms and severe 
exacerbations should be rare. Monitoring of asthmatic symptoms is a key feature of the 
management of asthma to evaluate the response to therapy and to titrate ICS dose to the 
lower effective dose (1). 
Whereas symptoms and lung function can be easily monitored, assessment of 
airway inflammation is more difficult and non-invasive markers of airway inflammation 
are preferred to more invasive tests like bronchoscopy. The evaluation of airway 
inflammation associated with asthma may be undertaken by examining spontaneously 
produced or hypertonic saline-induced sputum for eosinophilic or neutrophilic 
inflammation or by analysis of exhaled breath condensate in which some inflammatory 
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compounds are detectable. In addition, levels of fractional exhaled nitric oxide (FeNO) 
have been suggested as non-invasive markers of airway inflammation in asthma (2).  
 
Nitrogen oxides (NOx), regarded in the past primarily as toxic air pollutants, 
have recently been shown to be bioactive species formed endogenously in the human 
lung. The relationship between the toxicities and the bioactivities of NOx must be 
understood in the context of their chemical interactions in the pulmonary 
microenvironment. Nitric oxide synthase (NOS) is a newly identified enzyme system 
active in airway epithelial cells, macrophages, neutrophils, mast cells, autonomic 
neurons, smooth muscle cells, fibroblasts, and endothelial cells (figure 1).  
 
Figure 1: sites of NOS activity in the lung; the asterisks (*) mark cell types in which 
NOS activity has been demonstrated (from ref 3). 
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The chemical products of NOS in the lung vary with disease states, and are 
involved in pulmonary neurotransmission, host defence, and airway and vascular 
smooth muscle relaxation. Both endogenous and exogenous NOx react readily with 
oxygen, superoxide, water, nucleotides, metalloproteins, thiols, amines, and lipids to 
form products with biochemical actions ranging from bronchodilation and bacteriostasis 
(S-nitrosothiols) to cytotoxicity and pulmonary capillary leak (peroxynitrite), as well as 
those with frank mutagenic potential (nitrosamines). Nitric oxide (NO) is a mediator of 
vasodilatation and bronchodilatation synthesised from L-arginine by the enzyme NO 
synthase, which is either constitutive or induced by lipopolysaccharides and/or 
cytokines (3). 
The role of nitric oxide in airway inflammation was first reported in 
international medical journals in the beginning of the 80‟. To investigate the presence of 
NO synthase in asthma, Hamid and collaborators immunostained bronchial biopsies 
from non-steroid-treated people with asthma and non-asthmatic controls with specific 
polyvalent antisera to purified inducible NOS and to a selected peptide sequence of the 
same enzyme (4). Immunoreactivity was seen in the epithelium and some inflammatory 
cells in 22 of 23 biopsies from people with asthma, but in only 2 of 20 controls. To 
assess the relation of cytokines to NOS induction, bronchial epithelial cells in culture 
were stimulated with tumour necrosis factor (TNF alpha). Inducible enzyme 
immunoreactivity was found only in the treated cells. The existence of inducible NOS 
in human lungs suggests that increased production of NO, probably induced by 
cytokines, may be relevant to the pathology of asthma. 
Kharitonov and colleagues measured FeNO in 67 control subjects and 61 non-
steroid-treated asthmatics demonstrating that asthmatics had a significantly higher peak 
of FeNO as compared to healthy subjects (figure 2). These high concentrations may 
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reflect induction of NOS and measurement of FeNO concentrations may be clinically 
useful in detection and management of cytokine-mediated inflammatory lung disorders 
(2).   
 
 
 
 
Figure 2: representative original traces of exhaled NO in normal subject and asthmatic 
patient (from ref 2). 
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INHALED STEROIDS AND FeNO MEASUREMENT 
 
A factor influencing FeNO measurements is antinflammatory therapy as it has 
been observed that FeNO is elevated in untreated patients with asthma but not in 
patients treated with ICS (figure 3). This may reflect an inhibitory effect of 
glucocorticoids on the induction of the enzyme NO synthase in the respiratory tract (2).  
 
Figure 3: peak FeNO concentrations in control subjects (n=67), untreated asthmatic 
(n=61) and treated asthmatic (n=52) groups (from ref 2). 
 
Kharitonov and colleagues studied the effect of an ICS (budesonide 800 
micrograms twice daily via a dry powder delivery system for 3 weeks) on exhaled NO 
in 11 patients with mild asthma in a double-blind crossover randomized-order placebo-
controlled study. FeNO was significantly reduced from a baseline value of 203 ± 29 
parts per billion (ppb) to 120 ± 26 ppb after 3 weeks of treatment, whereas there was no 
change after a matched placebo (169 ± 20 ppb at baseline compared with 184 ± 16 ppb 
after 3 weeks). A significant and progressive fall in FeNO was found from week 1 to 3. 
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 In the same trial, no significant change in forced expiratory volume in one 
second (FEV1) after inhaled steroids was observed (although mean FEV1 was 92% 
predicted normal at baseline), although there was a reduction in airway responsiveness 
to methacholine (approximately 2.5 doubling dilutions). These results add further 
support to the view that the elevated levels of FeNO in asthma may derive from 
induction of an inducible isoform of NOS and indicate that FeNO may be a useful way 
of monitoring the anti-inflammatory effects of glucocorticoids and other anti-
inflammatory treatments in asthma (5).  
Silkoff et al. (6) determined the dose response and the reproducibility of the 
FeNO fall following inhaled beclomethasone dipropionate (BDP) therapy in non-
steroid-treated asthmatic patients. For four 1-week periods (period 1 to period 4), the 
following regimens were administered to 15 non-steroid-treated asthmatic patients 
received in sequential order placebo and 3 increasing BDP doses (100, 400 and 800 
µg/day). After 1 week at each dose level, the subjects came to the laboratory for 
measurement of FeNO. 
FeNO levels fell progressively from visit 1 to visit 5 and all doses of BDP 
resulted in a significant change in FeNO from placebo treatment, but with significant 
separation of only the 100µg and 800µg doses (figure 4). A post hoc inspection 
separated subjects into those with baseline FeNO of 60 to 100 ppb (n=6) and >100 ppb 
(n=9), on the assumption that airway inflammation would be mild to moderate and 
moderate to severe in these two groups, respectively. The low-FeNO group showed a 
modest fall in FeNO with 100 µg/day, but no further decline in FeNO as the dose of 
BDP was increased. The high-FeNO group showed a progressive fall in FeNO at each 
dose level, eventually reaching a similar level of FeNO as the low-FeNO group (figure 
4). 
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Figure 4: change in FeNO at each visit corresponding to baseline, placebo treatment, 
and then increasing doses of BDP. The FeNO trend for all the subjects (n = 15) is 
shown together with separate trends for high-baseline (n = 6) and low-baseline (n = 9) 
FeNO groups (from ref 6). 
 
Reproducibility was assessed in a four periods study in which 12 non-steroid-
treated asthmatic patients received placebo treatment for 7 days (period 1), 200 µg/day 
of BDP for 14 days (period 2), washout on placebo treatment until the FeNO was within 
15% of baseline (period 3), and 200 µg/day of BDP for 14 days (period 4). There were 
no significant differences between FeNO in the two placebo periods or between the two 
BDP periods, confirming that the fall in FeNO after two identical administrations of 
BDP separated by placebo washout was highly reproducible (figure 5). 
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Figure 5: changes in FeNO (mean ± SD) in two placebo periods and two periods of 
treatment with 200µg/day of BDP (steroid; from ref 6). 
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SMOKING AND FeNO MEASUREMENT 
 
Another factor influencing FeNO levels in exhaled air is smoking. The first 
study reporting measurements of FeNO concentrations in asthmatic outpatients and in 
non-smoking and smoking healthy controls was published in The Lancet in 1994. 
Persson and collaborators (7) demonstrated that in single exhalations, FeNO showed a 
peak suggestive of airway origin in both controls and asthmatic patients. The peak 
FeNO concentration was higher in asthmatic patients and lower in smokers than in non-
smoking controls (figure 6). The findings support a role for NO in the host defence 
response in asthma and suggest that FeNO measurements can discriminate between 
different types of lung disorders. These findings have implications for the use of FeNO 
measurements in asthmatic smokers that can be up to one third of the total asthmatic 
population.  
 
Figure 6: mean (SEM) peak FeNO concentrations in single exhalations after 15-s breath 
holding in healthy controls, asthmatic patients and smokers (from ref 7). 
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The mechanism by which smoking causes FeNO reduction is not fully 
understood, but may include reduction in NO synthesis due to feedback inhibition 
induced by high concentrations of NO contained in cigarette smoke. NO oxidation or 
interaction with other molecules present in tobacco smoke might also occur. However, 
regardless of the mechanism of FeNO reduction reported in smokers, it is generally 
assumed that FeNO should not be assessed in asthmatic patients who smoke. Perhaps, 
consequently, this population has been excluded from clinical trials that have explored 
the potential of FeNO as a biomarker in asthma management.  
Interestingly, Michilis et al. strongly suggested that it is the change in FeNO 
values, rather than absolute cut-off points (i.e. individualised FeNO profiles), that may 
be meaningful for the longitudinal assessment of asthma control in daily practice (8). 
Therefore, in a study recently published in the European Respiratory Journal (9), the 
authors investigated whether, despite the FeNO reduction reported in smoking asthma 
patients, changes in FeNO might also be significantly related to changes in asthma 
control in this population. To do this, FeNO was monitored on several occasions in 
smoking and non smoking patients attending a tertiary asthma clinic. Its ability to 
reflect improvement or worsening of asthma control over time was compared in both 
groups, using the Asthma Control Questionnaire (ACQ) as a gold standard for the 
assessment of asthma control. FeNO and the Asthma Control Questionnaire (ACQ) 
were recorded at least once in 411 non smoking (345 with at least two visits) and 59 
smoking (51 with at least two visits) asthma patients. The study confirmed that, 
compared with non smokers, FeNO is reduced in smoking asthma patients (18.1 ppb 
versus 33.7 ppb) despite similar mean ACQ scores (1.5 versus 1.7).  However, this 
reduction does not appear to suppress its ability to reflect asthma control in smoking 
patients, provided changes in FeNO values detected by repeated measurements are 
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considered. In fact, a decrease in FeNO of less than 20% precludes asthma control 
improvement in non smoking (negative predictive value, NPV=78%) and in smoking 
patients (NPV=72%).  
An increase in FeNO of less than 30% is unlikely to be associated with 
deterioration in asthma control in both groups of patients (NPV=86% and 84% in non 
smoking and smoking patients, respectively). Overall, the importance of sequential 
FeNO measurements in both smokers and non smokers is to distinguish whether or not 
ongoing changes or a sudden change in respiratory symptoms are/is due to changes in 
airway inflammation, possibly requiring a change in anti-inflammatory therapy. It is 
concluded that, even in smokers, sequential changes in FeNO have a relationship with 
asthma control, indicating that cigarette smoking does not obviate the clinical value of 
measuring FeNO in asthma among smokers. Moreover, it has been suggested that the 
effect of smoking on FeNO lasts no longer than 15-30 min and can be ignored by 
simply asking the patient on the time of the last cigarette and not making FeNO 
measurement earlier than 30 min after that. 
When considering both smoking and ICS therapy as two known factors affecting 
FeNO measurements, interestingly, in the study by Michilis et al. (9) when patients 
were treated with high-to-medium ICS doses, FeNO no longer had the ability to reflect 
an improvement in asthma control for smoking patients, whereas for non smoking 
patients, its ability was only slightly reduced. A similar trend was observed with respect 
to asthma control deteriorations. These results confirm the overall reduction of the 
ability of FeNO to reflect asthma control in patients treated with high-to-medium ICS 
doses. In addition, it appears that confounding factors, such as high ICS doses and 
tobacco smoking, which are known to reduce FeNO, would have a cumulative 
interfering effect that may eventually suppress the ability of FeNO to reflect asthma 
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control. This suggests that the effect of these confounding factors might have to be 
taken into account when using FeNO to assess asthma control.  
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MULTIPLE FLOWS FeNO MEASUREMENT 
 
As long as it is strongly agreed that peripheral airways are involved in the 
pathogenesis of asthma and inflammation is widely present in the whole bronchial tree 
including peripheral bronchioles and alveoli (1, 10), several tests have been proposed to 
measure the level of peripheral airway inflammation (11). FeNO measured at 50 ml/s 
mainly assesses the bronchial origin of exhaled NO, whereas alveolar NO concentration, 
measured in the compressible compartment, implicates deep lung inflammation. Two 
compartment models of pulmonary NO production have been described (12) which can 
be used to calculate the alveolar contribution to exhaled NO concentration by using a 
model of NO diffusion in airways and measurements of exhaled NO concentrations at 
multiple flow rates (13).  
 In a study by Berry et al. (14) in 13 normal subjects, 25 mild to moderate 
asthmatics and 27 patients with refractory asthma, a positive correlation was found 
between alveolar NO concentration and bronchoalveolar lavage (BAL) eosinophil count 
(figure 7) but not with bronchial wash or sputum eosinophil count. Alveolar NO 
concentration was increased in patients with refractory asthma compared with mild-to-
moderate asthma and normal controls and reduced by treatment with prednisolone 
(figure 8). These findings support the hypothesis that alveolar nitric oxide is a measure 
of distal airway inflammation and suggest that distal lung inflammation is present in 
refractory asthma.   
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Figure 7: Association between bronchoalveolar lavage (BAL) eosinophils and alveolar 
NO concentration (r=0.79, p=0.006; from ref 14). 
 
 
Figure 8: Alveolar NO concentration in normal controls compared to mild-to-moderate 
asthma and refractory asthma. ●: steroid naive; ○: inhaled steroid treated only; ■: oral 
and inhaled steroid treated. ***: p<0.001; NS: non significant (from ref 14). 
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Despite the evidence of a reduction in alveolar NO with oral corticosteroids (14), 
unlike bronchial NO, alveolar NO production is not reduced by ICS in patients with 
asthma, suggesting that it may be derived from a site not accessed by the inhaled drug 
(figure 9).  
 
Figure 9: Changes in alveolar NO concentration in patients who received a doubling of 
their inhaled steroid dose (n=10) and those who received oral corticosteroids (n=11). #: 
p=0.034; ¶: p=0.002; NS: non significant (from ref 14). 
 
However, partitioning exhaled NO in its bronchial and alveolar sources deserves 
further scrutiny. Although it has been recently suggested that the small airway 
epithelium is the major source of NO production (15), multiple sources have been 
identified in the lungs and several analytical
 
techniques have been developed to capture 
this rich feature (16, 17).  
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RECENT EVIDENCE ON FeNO MEASUREMENT 
 
The use of FeNO to monitor the effectiveness of asthma treatment is increasing 
because of its reported association with the presence of inflammation in asthma. For this 
reason, in the last decade 257 clinical trials in humans were published on the topic of 
nitric oxide and asthma (18). To standardize FeNO measurement methods, a guideline 
was released by the European Respiratory Society and the American Thoracic Society 
in the year 2005 (19).  
NO is commonly measured in respiratory clinics with a stationary machine that 
is similar in appearance and dimensions to a desktop computer, connected to a nitric 
oxide tank used for calibration. In the last 5 years, a small, portable NO analyzer was 
introduced to allow repeated measurements by patients outside the clinics. One of the 
trials evaluating the usefulness of this portable NO analyzer was conducted in UK 
general practice in collaboration with the University of Parma, Department of Clinical 
Sciences (20). The study involved 96 asthmatic patients and demonstrated that FeNO 
measurements performed with a new hand-held monitoring device are reproducible, 
simple and feasible in General Practice in the majority of patients of different age and 
asthma severity. Indeed, Success rate of FeNO measurements was 78% and the intra-
subject coefficient of variation was 8.7%. Moreover, an overall reducing effect of ICS 
on FeNO regardless of the smoking habit of the patients was demonstrated. Inhaled 
corticosteroid treatment had an overall reducing effect on the FeNO value vs. patients 
not on the ICS. Finally, a high percentage of patients with different severities of asthma 
and regardless of their treatment with ICS and current smoking habit (current and/or ex-
smokers) had highly elevated FeNO levels still significantly above the normal values, 
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suggesting that their current therapy was possibly insufficient to control the underlying 
degree of airway inflammation and asthma symptoms. 
The availability of FeNO measurements raised the question whether this could 
be a valid and convenient alternative to standard methods for diagnosis and monitoring 
of asthma. Price at al. (21) constructed two decision trees to compare FeNO 
measurement with standard diagnostic testing and guideline recommendations for 
management. The use and cost of each strategy, as well as associated outcomes, such as 
diagnostic accuracy, are derived from the medical literature. For asthma diagnosis, 
FeNO measurement was compared with lung function and reversibility testing, 
bronchial provocation and sputum eosinophil count. For asthma management, the 
impact on asthma control, including inhaled corticosteroid use, exacerbations and 
hospitalizations, of monitoring with FeNO measurement vs symptoms and lung function 
was evaluated as in standard care. Resource use (direct costs calculated from a UK 
health-care payer perspective) and health outcomes were evaluated over a 1-year time 
frame. The conclusion of this study is that asthma diagnosis based on FeNO 
measurement alone is less costly and more accurate than standard diagnostic methods 
and asthma management based on FeNO measurement is less costly than asthma 
management based on standard guidelines and provides similar health benefits. The 
application of FeNO measurement in clinical practice can therefore play an important 
role in diagnosing and assessing airway disease. 
As long as FeNO measurements are used to interpret the aetiology of 
nonspecific respiratory symptoms, identify potential responders to ICS therapy, and 
monitor underlying disease activity in asthma, there are significant areas of uncertainty 
regarding how results ought to be interpreted, especially in the treatment of patients 
with chronic asthma over time. This is because, unlike induced sputum eosinophils, 
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which are absent unless airway inflammation is present, a number of non pathological 
factors may influence FeNO, occasionally giving rise to increased levels even in healthy 
individuals. 
Clinically significant cut-points for FeNO have been based on the relationship 
between FeNO and induced sputum eosinophil counts, as well as levels which are 
prognostically important in relation to ICS therapy. In general, low FeNO values (<25 
parts per billion [ppb]) are associated with minimal airway eosinophilia (22). In patients 
with diagnosed asthma, this generally implies good asthma control or, if the patient is 
symptomatic, the need to consider explanations for their symptoms other than active 
eosinophilic airway inflammation. Conversely, high FeNO values (>50 ppb) indicate 
active eosinophilic airway inflammation and the likelihood of deterioration in asthma 
control if the dose of ICS is reduced, even if the patient is asymptomatic (22). However, 
this broad approach leaves open some unresolved questions as some patients with 
asthma may have FeNO levels that are higher than normal despite good asthma control 
and it is possible that individualized personal best values might be more clinically 
useful than population-derived reference values. Indeed, values deemed to be clinically 
normal and abnormal should perhaps be based on FeNO levels obtained when an 
individual patient‟s asthma is respectively well controlled and poorly controlled.  
To address this issue, Smith and colleagues (23) analyzed data obtained before 
and after a trial of oral prednisone (30mg/d for 14 days), and also from a previously 
published study in which patients had their dose of inhaled corticosteroid adjusted using 
either FeNO or symptoms/lung function to optimize treatment. The aim of the study 
was to identify the relationship between reference values for FeNO and personal best 
levels obtained after a course of oral prednisone in patients with mild to moderate 
persistent asthma. Secondly, a comparison of the personal best FeNO levels after 
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prednisone with those obtained at loss of control and during optimized treatment with 
inhaled steroid was performed. These comparisons were designed to clarify whether 
anti-inflammatory treatment ought to be guided by reference values or individual 
clinically-based cut-points for FeNO. 
Overall, data from Smith et a. indicate that when measuring FeNO in relation to 
asthma control and its treatment, target FeNO levels based on group mean data or 
reference equations have limited value. The absolute values and/or the magnitude of 
changes in FeNO in relation to personal best obtained in individual patients when 
asthma is well controlled are more likely to be informative. However, personal best 
FeNO levels in patients with asthma who have high levels when they are symptomatic 
do indeed coincide with a particular set of predicted values (24). 
The interrelationships between the fraction of FeNO, eosinophilic airway 
inflammation and steroid responsiveness, together with the ease with which FeNO may 
be measured, have prompted a series of randomized trials designed to confirm that 
using FeNO to optimize ICS therapy will improve asthma outcomes. Overall, we must 
accept that, notwithstanding any weaknesses of the various FeNO-based treatment 
algorithms, the routine use of FeNO in this setting does not fulfil earlier expectations 
(25). A recent Cochrane systematic review (26) including six studies (2 adults and 4 
children/adolescent) evaluated the efficacy of tailoring asthma interventions based on 
exhaled nitric oxide in comparison to clinical symptoms (with or without 
spirometry/peak flow) for asthma related outcomes in children and adults. Of 1053 
participants randomised, 1010 completed the trials. In the meta-analysis, there was no 
significant difference between groups for the primary outcome of asthma exacerbations 
or for other outcomes (clinical symptoms, FeNO level and spirometry). In post-hoc 
analysis, a significant reduction in mean final daily dose inhaled corticosteroid per adult 
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was found in the group where treatment was based on FeNO in comparison to clinical 
symptoms, (mean difference -450 mcg; 95% CI -677 to - 223 mcg budesonide 
equivalent/day). However, the total amount of inhaled corticosteroid used in one of the 
adult studies was 11% greater in the FeNO arm. In contrast, in the paediatric studies, 
there was a significant increase in inhaled corticosteroid dose in the FeNO strategy arm 
(mean difference of 140 mcg; 95% CI 29 to 251, mcg budesonide equivalent/day). 
It can be concluded that tailoring the dose of inhaled corticosteroids based on 
exhaled nitric oxide in comparison to clinical symptoms found only modest benefit at 
best and potentially higher doses of inhaled corticosteroids in children. The role of 
utilising exhaled nitric oxide to tailor the dose of inhaled corticosteroids cannot be 
routinely recommended for clinical practice at this stage and remains uncertain. It is 
understandable, but perhaps unfortunate, that the most rigorous studies to date have 
focused narrowly on how FeNO might be used to improve asthma outcomes in relation 
to ICS treatment. However, the pathophysiology of airway disease is heterogeneous, 
with many overlap syndromes giving rise to nonspecific symptoms which are only 
weakly correlated with abnormal lung function. FeNO measurements shed 
complementary light on the underlying inflammatory phenotype and, more importantly, 
on the potential response to antiinflammatory treatment. This was first assessed either 
by empiric „„trials of steroid‟‟ or, with reference to before/after changes in spirometry, 
whereas serial or repeated FeNO measurements in individual patients may provide 
additional diagnostic as well as prognostic insights (25). 
That „„asthma is a chronic inflammatory disorder‟‟ has been shouted from the 
rooftops for over 20 years, and the case for assessing airway inflammation in clinical 
practice has been strongly made. Practical issues have impeded the wider use of other 
non-invasive markers of inflammation such as induced-sputum and exhaled-breath 
 24 
condensate techniques. The standard of proof to support the adoption of FeNO, which is 
more accessible, ought to be rigorous but not narrowly focused. A working party of the 
American Thoracic Society is currently drawing up guidelines for the clinical use of 
FeNO measurements, and we await their statement with interest (25). 
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CONCLUSIONS 
 
FeNO is a non invasive marker of airway inflammation easy to be performed 
and can be helpful as a tool contributing to asthma diagnosis and evaluation of response 
to antinflammatory therapy with ICS. FeNO peak is increased in asthmatics, as 
compared to normal subjects and is lowered by ICS with a dose-response relationship 
that is more evident for asthmatic patients with high levels of FeNO. Smoking affects 
FeNO measurements and this has to be considered when evaluating patients with 
asthma who smoke, However, the change in repeated measures in the same patient, 
even if smoker,  can be meaningful for the longitudinal assessment of asthma control in 
daily practice. The clinical application of FeNO still needs to be clarified but it is 
clearly one of the most used non-invasive markers giving information on the 
inflammatory component of the disease. The possibility of measuring FeNO derived 
from either bronchial or alveolar regions by models dividing the lungs in two or more 
compartments can give information on the distribution of inflammation in the bronchial 
tree and is of particular interest for clinical pharmacology. The recent development and 
clinical application of new formulations of ICS which deliver small drug particles, able 
to reach the more peripheral airways, is of interest because inhaled therapy was limited 
to the proximal airways in the past. Several studies evaluated the usefulness of 
measuring FeNO in adults and children but few data are available regarding the 
different measurement of bronchial and alveolar FeNO which can be particularly useful 
to optimize therapy in patients with evidence of high values of alveolar FeNO. Future 
studies and the upcoming American Thoracic Society guidelines for the clinical use of 
FeNO measurements will clarify the clinical value of this important tool. 
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ABSTRACT  
 
Background: Exhaled nitric oxide (NO) is a non-invasive marker of airway 
inflammation. Beclomethasone dipropionate (BDP) is the only inhaled corticosteroid 
available as both extrafine and non-extrafine HFA pMDI formulation. The present study 
was designed to evaluate whether the different patterns of lung deposition of two HFA 
BDP formulations, are associated with a different effect on bronchial and alveolar NO.  
Methods: This was a prospective double blind, randomized, controlled, cross-over study. 
After a 2-week placebo run-in period without inhaled corticosteroids, asthmatic patients 
were randomized to extrafine BDP 100 µg bid or non-extrafine BDP 250 µg bid for two 
2-week periods separated by a 2-week washout period. 
Results: 14 patients (5 males) mean age 37 years, mean baseline FEV1 83 % of 
predicted were analyzed. Exhaled bronchial NO was significantly (p<0,001) reduced in 
both treatment groups as compared to the last week of run-in period, whereas alveolar 
NO was significantly (p<0,001) reduced only with extrafine BDP. Moreover, extrafine 
BDP was superior to non-extrafine BDP in both parameters (p<0,05). 
Conclusions: extrafine but not non-extrafine BDP HFA formulation lowers both 
bronchial and alveolar exhaled NO in asthmatic patients. ICS
 
distribution throughout the 
whole bronchial tree could be important in patients who do not gain optimal control of 
inflammation
 
with conventional non-extrafine ICS. 
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INTRODUCTION  
 
Asthma is a chronic inflammatory disease characterised by symptoms of variable 
severity associated with functional alterations and pathological abnormalities such as 
airway inflammation and remodelling. Anti-inflammatory treatment with inhaled 
corticosteroids (ICS) constitutes the cornerstone of asthma management and is the most 
effective long-term therapy [1]. 
Airway inflammation is present in all forms of asthma including mild and asymptomatic 
cases [2] and involves both large and small airways [3, 4], the latter  gaining attention 
over the past 15 years thanks to more specific and new non-invasive assessing 
techniques [5]. 
The fractional concentration of exhaled nitric oxide (FeNO) is one of the most widely 
used and convenient non-invasive markers in exhaled breath to monitor airway 
inflammation in adults and children [6,7]. NO is a gaseous signalling molecule 
participating in airway physiology, which levels are increased even in mild asthmatics 
and both in allergic and nonallergic asthma [8-10]. FeNO derives from endogenous NO 
production by synthases present in airway epithelium and inflammatory cells, with 
genetic factors accounting for a large proportion of the variation in FeNO and for the 
correlation between FeNO and serum total IgE [11, 12]. FENO originates from the 
intrapulmonary airways in asthma [13] and two compartment models of pulmonary NO 
production have been described [14], which can be used to calculate the bronchial (JNO) 
and alveolar contribution (Calv) to exhaled NO concentration [15]. 
 Calv is elevated in conditions associated with distal lung inflammation, such as 
alveolitis [16] and chronic obstructive pulmonary disease [17] and has been related to 
BAL  eosinophil cationic protein levels in asthmatic children [18] and to BAL 
eosinophil counts in asthmatic adults [19].  
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The need for treating asthma inflammation uniformly throughout the lower airways and 
has led to the introduction of extrafine ICS with small-particle formulation as a particle 
size of 3–5 µm is optimal for delivery to the conducting airways but particle sizes of 1 
µm (extrafine) are needed to target the smaller airways too [20].  
The switch from CFC to HFA-propelled MDIs leads to the reformulation of 
beclomethasone dipropionate (BDP) both as extrafine and non-extrafine formulation 
[21]. Small-particle aerosols, such as extrafine BDP, which have particle sizes around 1 
µm have been shown to allow a greater lung deposition of the drug as a proportion of 
ex-actuator amount, resulting in an equivalent dose ratio of 1:2,5 with non extrafine 
formulations [21] and a greater proportion that deposits peripherally [22].  
There is little doubt from the large body of published evidence that extrafine 
formulations are effective in improving clinical indices of asthma control, lung function 
and inflammation as well as traditional formulations and some evidence is available 
supporting an added benefit of extrafine formulations [23-24]. Whether small particles 
are better than larger particles in terms of their effect on small airway function, however, 
is an area of conflicting evidence and studies designed to address this question are often 
biased by using different drugs and/or devices [25-26].  
The present study was designed to evaluate whether the different patterns of lung 
deposition of two BDP HFA formulations (extrafine 100µg vs. non-extrafine 250 µg), 
are associated with a different effect on bronchial and alveolar exhaled nitric oxide in 
adults with mild to moderate asthma. 
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METHODS 
Subject characteristics 
Sixteen mild to moderate asthmatic patients (FEV1>60%)  according to GINA 
guidelines (1) with FeNO >40 ppb (standard flow 50ml/s) were screened and 14 
participated in the study. Patients were recruited by a pneumologist from outpatient 
clinic at the Parma University Hospital between April and July 2008.  
All patients had a diagnosis of asthma and objective measures of airway responsiveness 
and/or documented airway obstruction and a positive skin-prick test result to at least 
two common allergens (cat dander, house dust mite, grass pollen, Aspergillus 
fumigatus). Current smokers and patients with a smoking history of > 5 pack-years were 
excluded. Patients with near fatal asthma, evidence of symptomatic respiratory lower 
tract infection in the 8 weeks preceding the screening visit, hospitalization for asthma or 
patients on 3 or more courses of oral corticosteroids in the previous 6 months were not 
included. Additionally, patients were excluded if treated with anticholinergic agents or 
antihistamines in the previous 2 weeks and/or inhaled or intranasal corticosteroids or 
leucotriene receptor antagonists in the previous 4 weeks. 
None of the patients were receiving food supplements containing L-arginine, and none 
were on a nitrate-rich or nitrate-restricted diet that might influence exhaled NO levels. 
During the study, diaries were supplied to assess patients‟ compliance to treatments 
calculated in terms of % of the prescribed daily dose. Compliance was assessed with 
diary cards and accepted as sufficient when 75% of scheduled treatment was assumed. 
The study was performed in accordance with the Good Clinical Practice guidelines 
recommended by the International Conference on Harmonization of Technical 
Requirements, was approved by the Ethics Committee of University Hospital of Parma, 
and all participants gave written informed consent before inclusion.  
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Study Design 
This was a randomized, double-blind, double-dummy, cross-over design study. The 
whole study period was 8 weeks, during which patients were evaluated in 9 visits (Fig. 
1).  
 Patients satisfying inclusion and exclusion criteria entered the 2-week run-in period and 
all anti asthmatic drugs other than as needed salbutamol were withdrawn. Nasal 
decongestants were allowed for the treatment of hay fever. 
After a 2-week placebo run-in period, patients were randomized to receive extrafine 
BDP 100 µg bid (daily dose 200 µg) or non-extrafine BDP 250 µg bid (daily dose 500 
µg). Both treatments were administered by means of HFA pressurized metered dose 
inhalers (pMDI) for two 2-week periods, with a 2-week wash-out period in- between 
(Figure 1). The wash-out period was considered long enough to re-establish the original 
values of exhaled NO. To allow recovery of NO values, only the use of short-acting b2 
adrenergic agents was allowed, whenever needed, during the run-in and washout 
periods. 
 
Spirometry 
Spirometry was performed at each visit according to international recommendations [27] 
at least 6 h after administration of any short-acting beta-2 agonist. A flow-sensing 
spirometer connected to a computer for data analysis (Vmax 22, Sensor Medics, Yorba 
Linda, U.S.A.) was used for the measurements. The best value of three manoeuvres was 
expressed as absolute value (in litres) and as a percentage of the predicted value [28]. 
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Methacholine challenge 
Methacholine inhalation challenge was performed according to the European 
Respiratory Society guidelines [29]. Doubling increasing concentrations of 
methacholine from 0.03 to 32 mg/mL were delivered by a dosimeter (output, 9 μL per 
puff; MB3; Mefar; Brescia, Italy) and inhaled. Inhalations were interrupted when FEV1 
decreased by 20% from its post-saline solution value. The provocative dose of 
methacholine causing a 20% decrease in FEV1 was determined by linear interpolation 
of the last two experimental points. 
 
Exhaled NO measurements 
Exhaled NO concentration was measured by a chemiluminescence
 
analyzer (NIOX; 
Aerocrine AB; Stockholm, Sweden) at expiratory
 
rates of 10, 50, 100, 200, and 260 
mL/s by applying resistors
 
of 10, 50, 100, 200, and 300 cm H2O mL/s to maintain the 
target
 
flow rates. According to ATS/ERS guidelines [30], the patients were comfortably 
seated, inhaled NO-free
 
air from a reservoir, and then exhaled against different linear
 
resistors. The collection started when dead space time
 
was subtracted from start of 
exhalation. The analyzer was calibrated
 
with a known NO concentration (200 ppm). The 
exhalation time
 
was 20 s for 10 mL/s, 10 s for 50 mL/s and 100 mL/s, and 6 s
 
for 200 
mL/s and 260 mL/s. The minimum waiting time between
 
measurements was 20 s to 
allow the patient to rest.
 
 
JNO and Calv were calculated by nonlinear
 
regression according to the equation of George 
et al [15]. The slope
 
and the intercept of a regression line between NO output and
 
exhalation flow rate are Calv and JNO, respectively.  
 35 
STATISTICS 
Data are expressed as mean (SD) or ± SEM. The distribution of variables was assessed 
by means of Kolmogorov-Smirnov Goodness-of-Fit test. A non parametric Wilcoxon t 
test was used to compare NO values at the end of the second week of each treatment 
period versus baseline values (end of run-in). Statistical significance was set at p<0.05. 
Repeatability of JNO and Calv measurements was assessed with Bland–Altman analysis 
[31]. The mean values at all visits were plotted on the horizontal axis and the 
differences of the means at all visits plotted on the vertical axis which shows the amount 
of disagreement between the measures (via the differences) in order to see how this 
disagreement relates to the magnitude of the measurements. 
 
RESULTS 
 
All randomized patients completed the 8 week study period with satisfactory treatment 
compliance. Subject characteristics at baseline (visit 3) are shown in Table 1. Both 
extrafine and non-extrafine BDP lead to a significant reduction in JNO after 2 weeks 
treatment compared to baseline (1541 ± 138 pL/s and 1832 ± 142 pL/s vs. 2798 ± 222.9 
pL/s respectively; p<0.001; Figure 2). However, the JNO values were lower after 
treatment with BDP extrafine compared to non-extrafine (p<0.05; figure 2). 
By contrast, only extrafine BDP lead to a significant reduction from baseline 
(2.1 ± 0.1 ppb vs. 3.7 ± 0.1 ppb; p<0.001) in Calv, whereas non-extrafine BDP did not 
modify Calv levels (3.3 ± 0.2 ppb vs. 3.7 ± 0.1 ppb; Figure 3).  
The repeatability of JNO measurements as measured by the Bland–Altman 
analysis yielded an upper limit of agreement of 446 ppb and a lower limit of –535 ppb. 
The repeatability of Calv measurements as measured by the Bland–Altman analysis 
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yielded an upper limit of agreement of 0.80 ppb and a lower limit of –0.96 ppb (Figure 
4).  
No significant differences were observed in JNO and Calv when comparing the 
first with the second week of the run in, wash out, or treatment periods. 
No correlation was found between both JNO and Calv concentrations and lung 
function values. 
 
DISCUSSION 
 
The present study shows that in mild to moderate asthmatic patients only extrafine BDP 
reduced both JNO and Calv concentrations while non-extrafine BDP lead to a significant 
reduction in JNO values only. This finding suggests that treatment with extrafine BDP 
can specifically exert anti-inflammatory effects on both central and small airways in 
asthma.  
Previous studies investigating the effect of inhaled steroids on bronchial and alveolar 
derived NO are available but providing discordant results. The reduction of JNO but not 
Calv with non extrafine BDP is consistent with previous results obtained with a non-
extrafine fluticasone dry powder formulation in patients with asthma confirming that 
Calv may be derived from a site not accessed by non-extrafine inhaled corticosteroid 
treatment [16]. By contrast, Robroeks and colleagues failed to demonstrate a different 
effect on JNO and Calv when comparing extrafine BDP with non-extrafine fluticasone dry 
powder inhaler (DPI) in children. These results were probably affected by overtreatment 
due to the relatively high doses of steroids compared and by the lack of sensitivity 
associated with the study design in which patients were treated with ICS during run-in 
period [26]. Furthermore, the significant reduction in Calv we found with extrafine BDP 
treatment is in agreement with the recently published data showing a reduction in Calv 
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after treatment with a recently developed extrafine formulation of an ICS, ciclesonide 
[32]. The present study comparing two HFA pMDI formulations of the same drug, BDP, 
provides the first evidence of a different distribution of the antinflammatory effect in the 
central and peripheral airways. This is reasonably due to the higher peripheral 
deposition of the extrafine formulation as any other variable such as different devices or 
different active drugs is lacking.  
In this study, Bland Altman analysis of JNO and Calv measurements demonstrated a high 
repeatability and clinically acceptable agreement.
 
A single operator made all 
measurements and the feasibility was further enhanced by the accuracy NO analyser
 
used, which controlled the exhalation parameters and ensured
 
that the measurements 
were not accepted unless they were performed
 
according to the guidelines. NO 
concentrations were increased during run-in and wash out periods demonstrating the 
presence of an ongoing active inflammatory process, and confirming the validity of the 
study design. Moreover, the lack of difference between the first and the second week of 
each study period suggests that both JNO and Calv levels are rapidly modified by both 
ICS treatment initiation and suspension without evidence of carry-over effect, at least 
when ICS are given at low doses for short periods as in the present study.  
Proper anti-inflammatory treatment requires accurate assessment and monitoring of the 
underlying inflammatory state of the airways and the lack of reduction in Calv levels 
after treatment with non-extrafine ICS, suggests that the inflammatory process in the 
peripheral airways is extensive and still relatively undertreated despite ICS 
administration. The current study shows that patients with normal JNO after non-
extrafine ICS treatment can still have room for improvement in Calv, thus suggesting 
Calv could be successfully used to adjust anti-inflammatory treatment, for example, by 
the addition of extrafine ICS or to test novel anti-inflammatory therapies. Indeed, 
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current asthma guidelines [1] recommend treatment based on the assessment of asthma 
control using symptoms and lung function but studies in many countries have identified 
that asthma control remains suboptimal despite the existence of effective asthma 
treatments [33]. The use of exhaled NO levels to guide therapy, especially as regards 
increase and reduction in ICS dose, although promising [7], is still a matter of 
discussion as different studies gave discrepant results probably due to study design 
characteristics [34]. Indeed, exhaled NO is a sensitive marker to assess the local anti-
inflammatory effects of ICS as it has been shown that levels of exhaled NO correlate 
with eosinophils in sputum, is predictive of a response to ICS and an elevated level of 
FeNO is predictive of asthma relapse following corticosteroid withdrawal [35,36]. 
Even if the correlation of Calv values with standard spirometry could be of particular 
interest to the potential clinical application, we did not find any correlation between Calv 
and lung function parameters, in agreement with previous findings [37], confirming that 
NO levels are not markers of airflow limitation.  
A formal power calculation was not performed when the study was designed, as no 
reference values were available as effect sizes of ICS on small airway parameters are 
not yet fully known. Notably, it is reassuring that other intervention studies evaluating 
effects of small-particle ICS used similar sample sizes [32,38-41].  
Although it has been recently suggested that the small airway epithelium is the major 
source of NO production [42], multiple sources have been identified in the lungs and 
several analytical
 
techniques have been developed to capture this rich feature.
 
The 
strength of the two-compartment model we used [14, 15] is its relative simplicity
 
in 
characterizing NO exchange dynamics. Moreover, this model is the only one described 
in ATS guidelines for NO measurements to distinguish between bronchial and alveolar 
NO production [30].  
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The reports so far still suggest the flow-independent NO parameters are
 
uniquely altered 
in several disease states such as asthma, cystic
 
fibrosis, scleroderma, alveolitis, COPD, 
and allergic rhinitis
 
and thus we believe provide pathophysiological insight or assist in
 
the clinical management of inflammatory lung diseases. The balance between model 
complexity and
 
ease of clinical translation is not yet optimal and provides
 
exciting 
opportunities for the future. 
In summary, the present study has demonstrated that treatment
 
with extrafine inhaled 
BDP,
 
at a daily dose of 100µg bid, improves both bronchial and alveolar exhaled NO in 
patients with asthma, suggesting a uniform and complete antinflammatory effect. Drug 
distribution throughout the whole bronchial tree with extrafine formulations could be 
important in patients who do not gain optimal control of inflammation
 
with 
conventional non-extrafine ICS. 
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Table 1. Subjects characteristics at baseline 
 
Variables Asthma 
(n=14) 
Age,years 37 (8) 
Sex, M/F 5/9 
FEV , L 2.96 (1.0) 
FEV , % predicted 83.0 (14.2) 
FVC, L 4.07 (1.0) 
FVC, % predicted 95.0 (11.2) 
FEV1/FVC (%) 71.6 (8.1) 
FENO 55.7 (18.3) 
PD20 mch FEV1, µg  198.55 (30-1438)
a
 
Definition of abbreviations: M=male; F=female; FEV1=forced expiratory volume in one second; 
FVC=forced expiratory vital capacity; PD20 mch FEV1= provocative methacholine dose causing a 20% 
fall in FEV1; Values are means (SD); 
a
geometric mean (range) 
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Figure Legends: 
Figure 1. Study design 
 
Figure 2. Effects of extrafine and non-extrafine BDP on bronchial nitric oxide (JNO). 
Results are expressed as mean±SEM. *p<0.001 vs baseline; # p<0.05 between 
treatments. 
 
Figure 3. Effects of extrafine and non-extrafine BDP on alveolar nitric oxide (Calv). 
Results are expressed as mean±SEM. *p<0.001 vs baseline; # p<0.05 between 
treatments. 
 
Figure 4. Bland-Altman analysis for the repeatability of JNO values (panel A) and Calv 
values (panel B).  
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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